DrugPatentWatch Database Preview

Synthon Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for SYNTHON PHARMS, and when can generic versions of SYNTHON PHARMS drugs launch?

SYNTHON PHARMS has twelve approved drugs.

There is one US patent protecting SYNTHON PHARMS drugs. There are four tentative approvals on SYNTHON PHARMS drugs.

Summary for Synthon Pharms

US Patents:	1
Tradenames:	10
Ingredients:	10
NDAs:	12

Drugs and US Patents for Synthon Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Synthon Pharms	ZOLPIDEM TARTRATE	zolpidem tartrate	TABLET, EXTENDED RELEASE;ORAL	078483-002	Jun 6, 2011		DISCN	No	No
Synthon Pharms	ZOLPIDEM TARTRATE	zolpidem tartrate	TABLET, EXTENDED RELEASE;ORAL	078483-001	Apr 12, 2011		DISCN	No	No
Synthon Pharms	RISPERIDONE	risperidone	TABLET;ORAL	078187-005	Oct 22, 2009		DISCN	No	No
Synthon Pharms	FLUVOXAMINE MALEATE	fluvoxamine maleate	TABLET;ORAL	075899-002	Jan 17, 2001		DISCN	No	No
Synthon Pharms	AMLODIPINE BESYLATE	amlodipine besylate	TABLET, ORALLY DISINTEGRATING;ORAL	022026-003	Sep 27, 2007		DISCN	No	No	6,828,339			Y
Synthon Pharms	LETROZOLE	letrozole	TABLET;ORAL	090196-001	Jun 3, 2011		DISCN	No	No
Synthon Pharms	ZOLPIDEM TARTRATE	zolpidem tartrate	TABLET;ORAL	077540-001	Apr 23, 2007		DISCN	No	No

Premature patent expirations for SYNTHON PHARMS

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

International Patents for Synthon Pharms Drugs

Country	Document Number	Estimated Expiration
European Patent Office	1448197
Australia	2002343257
Argentina	037565
World Intellectual Property Organization (WIPO)	03043635

Supplementary Protection Certificates for Synthon Pharms Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C0053	Belgium		PRODUCT NAME: LETROZOLE; NAT. REGISTRATION NO/DATE: 206 IS 241 F 3 19970616; FIRST REGISTRATION: FR 341 474.2 1996072
C/GB97/013	United Kingdom		PRODUCT NAME: LETROZOLE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: FR 341 474-2 19960724; FR 341 475-9 19960724; UK PL00001/0224 19961118
12/018	Ireland		PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705
C0048	France		PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
636	Luxembourg		PRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
07C/043	Belgium		PRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222
C/GB05/010	United Kingdom		PRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH SIMVASTATIN; REGISTERED: DE 58874.00.00 20040402; DE 58874.01.00 20040402; DE 58874.02.00 20040402; DE 58874.03.00 20040402; DE 58878.00.00 20040402; DE 58878.01.00 20040402; DE 58878.02.00 20040402; DE 58878.03.00 20040402; DE 58866.00.00 20040402; DE 58866.01.00 20040402; DE 58866.02.00 20040402; DE 58866.03.00 20040402; DE 58870.00.00 20040402; DE 58870.01.00 20040402; DE 58870.02.00 20040402; DE 58870.03.00 20040402; UK PL 19945/0003 20041118; UK PL 19945/0004 20041118; UK PL 19945/0005 20041118; UK PL 19945/0006 20041118; UK PL 19945/0007 20041118; UK PL 19945/0008 20041118; UK PL 19945/0009 200411

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Synthon Pharms